Literature DB >> 9023420

Simultaneous production of T helper-1-like cytokines and cytolytic activity by tumor-specific T cells in ovarian and breast cancer.

P S Goedegebuure1, C C Douville, J M Doherty, D C Linehan, K Y Lee, E K Ganguly, T J Eberlein.   

Abstract

Cytotoxic T-cell (CTL) cultures were generated from five ovarian cancer patients (OvCTL) and from three breast cancer patients (BrCTL). All CTL lines were T-cell receptor (TcR) alphabeta+ and predominantly CD8+ (73 +/- 13%). These CTL lines preferentially recognized autologous tumor cells in an HLA class I-restricted, and in part HLA-A2-restricted, manner. In addition, the CTL lines recognized allogeneic HLA-A2+ ovarian and breast tumor cells. Specific recognition was determined by T-cell-mediated cytotoxicity as well as cytokine release. Coculture of irradiated autologous tumor cells with OvCTL induced secretion of IFN-gamma, GM-CSF and TNF-alpha, but not IL-4, indicating a T helper-1-type response. Similar results were obtained when OvCTL and BrCTL were stimulated with histologically matched HLA-A2+ tumor cells. Also, BrCTL stimulated with HLA-A2+ but not HLA-A2- ovarian tumor cells produced significant levels of GM-CSF and TNF-alpha. Finally, the Her2/neu peptide p654-662, earlier identified as a tumor antigen in both ovarian and breast cancer, induced cytotoxicity as well as the specific release of IFN-gamma and TNF-alpha but not IL-4 by OvCTL and BrCTL. Thus, tumor-specific recognition by CTL was verified by cytotoxicity and cytokine release. The secretion of Th1-like cytokines as opposed to Th2-like cytokines suggest that therapeutically OvCTL and BrCTL could potentially enhance the endogenous immune response to tumor.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9023420     DOI: 10.1006/cimm.1996.1055

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  6 in total

Review 1.  Th1/Th2 balance in cancer, transplantation and pregnancy.

Authors:  M R Shurin; L Lu; P Kalinski; A M Stewart-Akers; M T Lotze
Journal:  Springer Semin Immunopathol       Date:  1999

2.  Recycled addition of CD4+ T cell-rich population for induction of human autologous cytotoxic T lymphocytes: A practically efficient method.

Authors:  K Saijo; H Tsurushima; K Tsuboi; T Nose; A Oki; T Ohno
Journal:  Cytotechnology       Date:  2000-10       Impact factor: 2.058

3.  Expression of Fas (CD95/APO-1) ligand by human breast cancers: significance for tumor immune privilege.

Authors:  J O'Connell; M W Bennett; G C O'Sullivan; J O'Callaghan; J K Collins; F Shanahan
Journal:  Clin Diagn Lab Immunol       Date:  1999-07

4.  Depressed and anxious mood and T-cell cytokine expressing populations in ovarian cancer patients.

Authors:  Susan K Lutgendorf; Donald M Lamkin; Koen DeGeest; Barrie Anderson; Minh Dao; Stephanie McGinn; Bridget Zimmerman; Heena Maiseri; Anil K Sood; David M Lubaroff
Journal:  Brain Behav Immun       Date:  2008-02-13       Impact factor: 7.217

5.  Reduced expression of chemokine (C-C motif) ligand-2 (CCL2) in ovarian adenocarcinoma.

Authors:  J M Arnold; P R Huggard; M Cummings; G A Ramm; G Chenevix-Trench
Journal:  Br J Cancer       Date:  2005-06-06       Impact factor: 7.640

6.  Tumor-infiltrating T cells correlate with NY-ESO-1-specific autoantibodies in ovarian cancer.

Authors:  Katy Milne; Rebecca O Barnes; Adam Girardin; Melanie A Mawer; Nancy J Nesslinger; Alvin Ng; Julie S Nielsen; Robert Sahota; Eric Tran; John R Webb; May Q Wong; Darin A Wick; Andrew Wray; Elissa McMurtrie; Martin Köbel; Steven E Kalloger; C Blake Gilks; Peter H Watson; Brad H Nelson
Journal:  PLoS One       Date:  2008-10-15       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.